Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New strategy developments in brain tumor therapy.

A A Brandes1, U Basso, L M Pasetto

  • 1Department of Oncology, Azienda Ospedale-Universita, Padova, Italy. aabrandes@unipd.it

Current Pharmaceutical Design
|September 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial.

ESMO open·2025
Same author

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.

ESMO open·2022
Same author

Development and validation of the Myasthenia Gravis TeleScore (MGTS).

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2022
Same author

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

ESMO open·2021
Same author

Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study.

BMC cancer·2020
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

New chemotherapy drugs like temozolomide show promise for treating malignant gliomas. Clinical trials are essential for developing improved therapies for these brain tumors.

Area of Science:

  • Neuro-oncology
  • Malignant Glioma Research
  • Chemotherapy Drug Development

Background:

  • Malignant gliomas are aggressive brain tumors with a significant incidence.
  • Tumor incidence increases with age, particularly in individuals over 70.
  • Current treatment involves surgery, radiation, and chemotherapy.

Purpose of the Study:

  • To review recent advancements in chemotherapy for malignant gliomas.
  • To discuss novel drugs, their targets, and treatment efficacy.

Main Methods:

  • Review of recent literature on chemotherapy for malignant gliomas.
  • Analysis of new drugs, including their cellular targets, objective response rates, time to progression (TTP), and median survival time (MST).

Main Results:

Related Experiment Videos

  • Temozolomide demonstrates encouraging efficacy and tolerability in recent studies.
  • Clinical trials involving CPT11 have also yielded positive outcomes.

Conclusions:

  • Novel chemotherapy approaches are crucial for improving outcomes in malignant glioma patients.
  • Patient enrollment in well-designed clinical trials is vital for generating new therapeutic information and advancing treatment options.